Gene editing is at the frontier of biotech innovation, driving capital investments and momentum within the IPO market. Learn more.

Take a closer look at the SPAC phenomenon with Dr. David Hung, Founder and CEO of Nuvation Bio and Michelle Doig.

Luca Issi, Senior Biotech Analyst at RBC Capital Markets, and Co-Founder of Vida Ventures Arjun Goyal discuss emerging modalities and investor trends.

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.